MindMed

Also Clin2 ADHD; MM-110 Clin2 opioid withdrawal; LSD Clin2 cluster headaches, Clin2 depression; MM-402 Clin0 autism spectrum disorder; 4 undisclosed programs Clin0/Clin1 undisclosed

MindMed, a NY-based biotech company was founded in 2019 and is at the forefront of psychedelic medicine for brain health disorders like addiction, anxiety, and ADHD. They aim to address unmet patient needs in psychiatry, pain, and neurology through the identification of novel drug candidates and development of digital therapeutics. MindMed is developing drugs inspired by psychedelics with fewer side effects and a more targeted result that should be combined with psychotherapy to improve patient outcomes. Their pipeline candidates target the serotonin, dopamine, and acetylcholine systems. Their approach is highly digital, allowing for in-session monitoring and predictive modeling. They also have collaborations with Universitätsspital Basel and Mindshift Compounds.